Yutaro Kubota

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma

Keiko Minashi, Keiji Nihei, Junki Mizusawa et al. · Gastroenterology · 2019 · 205 citations · Full text

Medicine, Oncology, Surgery +14

Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors

Kiyohiro Ando, Kazuyuki Hamada, Makoto Watanabe et al. · Anticancer Research · 2019 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Ken Kato, Yuichiro� Doki, Takashi Ogata et al. · Esophagus · 2022 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylation

YUSUKE AOKI, Qinghong Han, Yasunori Tome et al. · Frontiers in Oncology · 2022 · 50 citations · Full text

Medicine, Cancer Biology, Oncology +17